Status: Recruiting
RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD. * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly
Participants needed: 100
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Altimmune, Inc.Updated: Mar 20, 2026Locations: 43
Eligibility criteria
Male or female ages 18 to 75 years, inclusive [+3]
Presence of clinically significant alcohol withdrawal symptoms, defined as CIWA-... [+3]